ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Plasminogen Activator Inhibitor-1 is Internalized by Endothelial Cells via A Pinocytosis-Like Mechanism and Evades Degradation.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Plasminogen activator inhibitor 1 (PAI1) is a secreted protease inhibitor, but accumulating evidence supports a role for PAI1 in regulating intracellular processes. PAI1 is secreted in an active conformation that serves as a bait for plasminogen activators (PA). Interaction between PAs and PAI1 results in a covalent linkage. PAI1/PA bind LRP1 and uPAR on the cell surface, triggering internalization and degradation. However, it was recently shown that exogenous PAI1 directly interacts with endothelial nitric oxide synthase inside endothelial cells. Our objective was to characterize the non-degradative pathway for PAI1 internalization. We use a hemagglutinin (HA)-tagged construct of PAI1 to track endocytosis of exogenous PAI1 in cultured endothelial cells via Western blotting of cell lysates and immunofluorescence microscopy. We demonstrate that PAI1-HA is actively internalized through a non-receptor-mediated mechanism, independent of clathrin-mediated endocytosis or caveolae. PAI1-HA internalization was partially inhibited by a derivative of amiloride, an inhibitor of macropinocytosis, though it was independent of Rac1 and CDC42, GTPases used for macropinocytosis. After internalization, PAI1-HA evades degradation for at least 3 h. By contrast, PAI1/uPA is degraded within 30 min of internalization. PAI1-HA internalization is independent of LRP1 and uPAR. We propose a model whereby PAI1/PA is endocytosed by LRP1- and uPAR-dependent endocytosis, whereas latent PAI can be internalized through a pinocytic-like mechanism and evade degradation, facilitating paracrine signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.